📇 Rhumatologue · ST PIERRE DE COUTANCES · (50) · Libéral

M Florian BIRAIS

Pourquoi vous devez consulter ce praticien

2 raisons identifiées

Auteur de référence en rhumatologie
27 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
107.5 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 ST PIERRE DE COUTANCES (50)LibéralRPPS 10100549236

✨ Génération du profil synthétique IA en cours…

Lieu de consultation

CABINET DU DR Florian BIRAIS
11 RUE DES CARRIERES SAINT MICHEL, 50200 ST PIERRE DE COUTANCES
Activité de soin et de pharmacie

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

📊 Comprendre le remboursement

Prendre rendez-vous & contact

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Cannabidiol and Liver Enzyme Level Elevations in Healthy Adults: A Randomized Clinical Trial

JAMA internal medicine · 2025

📚 19 citations🎯 RCR 8.86🩺 Clinique🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

ImportanceThe wide use of unregulated cannabidiol (CBD) products among consumers raises safety concerns. Most research on CBD has studied the relatively high doses used by patients taking prescription CBD. However, limited safety data are available at lower doses.ObjectiveTo study the effects of 4-weeks of twice-daily CBD use on the liver and endocrine hormones using a dose within the range consumers are taking with unregulated CBD products.Design, Setting, and ParticipantsThis randomized double-blinded placebo-controlled trial from January to August 2024, using per protocol analysis, included healthy adults recruited from a clinical pharmacology unit (Spaulding Clinical Research in West Bend, Wisconsin).InterventionsHealthy participants were randomized to CBD, 5 mg/kg/d (2.5 mg/kg/d twice daily), or placebo for 28 days with weekly laboratory assessments.Main Outcomes and MeasuresThe primary end point was the percentage of participants with an alanine aminotransferase or aspartate aminotransferase level elevation greater than 3 times the upper limit of normal during the study.ResultsIn 201 healthy participants (median age, 36 years [IQR, 30-43 years]; 89 women [44%]), 8 participants (5.6%; 95% CI, 1.8%-9.3%) in the CBD group and 0 participants (0%; 95% CI, 0%-7.6%) in the placebo group had liver enzyme level elevation greater than 3 times the upper limit of normal. Seven participants met withdrawal criteria for potential drug-induced liver injury, detected at day 21 in 2 participants and day 28 in 5 participants. No differences in change from baseline were observed between the CBD and placebo groups for total testosterone and inhibin B in male participants or thyrotropin, total triiodothyronine, and free thyroxine in all participants.Conclusions and RelevanceIn this study, the incidence of elevated alanine aminotransferase or aspartate aminotransferase coupled with the finding of increased eosinophilia, underscores the need for further investigation on the long-term effects of CBD use, its impact on various populations, and the safety of lower doses commonly used by consumers.Trial RegistrationClinicalTrials.gov Identifier: NCT06192589

Combined TNF-α and OX40L targeting as a new treatment option for hidradenitis suppurativa

The journal of allergy and clinical immunology. Global · 2025

📚 8 citations🎯 RCR 3.59🔓 Open Access

Using AI-generated digital twins to boost clinical trial efficiency in Alzheimer's disease

Alzheimer's & dementia (New York, N. Y.) · 2025

📚 3 citations🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Abstract INTRODUCTION Machine learning models leverage baseline data to create artificial intelligence (AI)–generated digital twins (DTs)—individualized predictions of each participant's clinical outcomes if they had received placebo. Incorporating DTs may increase statistical power or reduce required sample sizes in Phase 2 or 3 trials, and therefore improve efficiency in Alzheimer's disease (AD) trials. Here we demonstrate these properties using data from an AD Phase 2 clinical trial (AWARE, NCT02880956). METHODS A conditional restricted Boltzmann machine (CRBM) model was trained on historical clinical trials and observational data from 6736 unique subjects after data harmonization to generate DTs of participants from the AWARE trial. The AWARE trial enrolled 453 subjects with mild cognitive impairment (MCI) or mild AD. DTs were assessed as prognostic covariates to evaluate gains in variance and sample size reduction. RESULTS Positive partial correlation coefficients were found between DTs and change score from baseline in key cognitive assessments ranging from 0.30 to 0.39 at Week 96 in the AWARE trial. These correlations were consistent with validation results from three independent trials, which ranged from 0.30 to 0.46. Total residual variance was reduced by ~9% to 15% with DTs. While maintaining statistical power, DTs could reduce total sample size by ~9% to 15%, and control arm sample size by 17% to 26% in future AD trials. DISCUSSION Efficiency was improved in AD clinical trials using machine learning models to generate prognostic DTs by including them in statistical analysis modeling. This methodology aligns with regulatory guidance and represents an application of machine learning models suitable for the analysis of pivotal trial data. Validated DTs have the potential to improve clinical development efficiency in AD and in other neurological indications. Highlights Digital twins (DTs) were generated by artificial intelligence (AI) models trained on historical datasets. Use of digital twin (DT) as a covariate in the analysis model can reduce treatment effect variability. By coupling DT with the analysis model, trial sample size can be reduced. DT technology was accepted by the U.S. Food and Drug Administration and European Medicines Agency for applications in clinical trials.

Cookies & analyse de trafic

M Florian BIRAIS

Pourquoi vous devez consulter ce praticien

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (27) — classées par pathologie

Transversal10

Essai clinique4

Revue générale4

Revue / méta-analyse2

Biomarqueurs / Auto-Ac1

Case report / série1

Économie santé1

Épidémiologie & registres1

IRM ostéo-articulaire1

Lupus1

Pharmacovigilance1

Qualité de vie / PROMs1

Santé mentale / fatigue1

Partager cette fiche